BRAF and neoplasm: In models additionally adjusted for treatment line, baseline tumor burden (number of target liver metastases, RECIST sum of target diameters, total tumor volume), and molecular markers (BRAF/MSI where available), Δ-GLCM Homogeneity remained independently associated with PFS (HR = 0.58, 95% CI 0.36–0.92, p = 0.021) and OS (HR = 0.61, 95% CI 0.38–0.98, p = 0.041) (Figure 4 and Figure 5).